On April 30, 2025, Windtree Therapeutics Inc. completed a securities purchase agreement raising $2.5 million from the sale of 3,125 shares of Series D Convertible Preferred Stock, which has a 10% annual dividend and a conversion price of $1.368 per share. The company also entered into an assignment agreement on April 19, 2025, involving a real estate purchase for approximately $43 million with specific conditions for liability and finalization by May 23, 2025.